Carlo M. Cipolla

TL;DR: Most cardiotoxicity after anthracycline-containing therapy occurs within the first year and is associated with anthrACYcline dose and LVEF at the end of treatment, suggesting early detection and prompt therapy of cardiot toxicity appear crucial for substantial recovery of cardiac function.

TL;DR: In cancer patients developing AC-CMP, LVEF recovery and cardiac event reduction may be achieved when cardiac dysfunction is detected early and a modern HF treatment is promptly initiated.

TL;DR: In high-risk, HDC-treated patients, defined by an increased troponin I value, early treatment with enalapril seems to prevent the development of late cardiotoxicity.

TL;DR: These new ESMO Clinical Practice Guidelines are the result of a multidisciplinary cardio-oncology review of current evidence with the ultimate goal of providing strict criteria-based recommendations on CV risk prevention, assessment, monitoring and management during anticancer treatment.

TL;DR: TNI+ identifies trastuzumab-treated patients who are at risk for cardiotoxicity and are unlikely to recover from cardiac dysfunction despite HF therapy.